Vinorelbine Injection USP 10 & 50 mg

Description

Vinorelbine  InjectionUSP 10 & 50 mg  is indicated in combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).It is also used as a single agent, for the treatment of patients with metastatic NSCLC.

There are many generic manufacturers in India who manufacture Vinorelbine  InjectionUSP 10 & 50 mg including fresenius-kabi etc.

3s corporation is Supplier,Exporter ,Wholesaler  for Vinorelbine  InjectionUSP 10 & 50 mg in India.

Additional Information

Side Effects

Hepatic Toxicity

Drug-induced liver injury manifest by elevations of aspartate aminotransferase and bilirubin can occur in patients receiving Vinorelbine alone or in combination with cytotoxic agents.

Severe Constipation and Bowel Obstruction

Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur with Vinorelbine administration.

Extravasation and Tissue Injury

Extravasation of Vinorelbine can result in severe irritation, local tissue necrosis and/or thrombophlebitis.

Neurologic Toxicity

Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving Vinorelbine.

Pulmonary Toxicity and Respiratory Failure

Pulmonary toxicity, including severe acute bronchospasm, interstitial pneumonitis, acute respiratory distress syndrome (ARDS) occurs with use of Vinorelbine. Interstitial pneumonitis and ARDS included fatalities. The mean time to onset of interstitial pneumonitis and ARDS after Vinorelbine administration was one week (range 3 to 8 days) .

Embryo-Fetal Toxicity

Vinorelbine can cause fetal harm when administered to a pregnant woman. In animal reproduction studies in mice and rabbits, embryo and fetal toxicity were observed with administration of Vinorelbine at doses approximately 0.33 and 0.18 times the human therapeutic dose, respectively. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to a fetus.

Pack Size